KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Gross Profit: 2009-2024

Historic Gross Profit for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $1.9 billion.

  • Alnylam Pharmaceuticals' Gross Profit rose 151.06% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 17.31%. This contributed to the annual value of $1.9 billion for FY2024, which is 24.46% up from last year.
  • According to the latest figures from FY2024, Alnylam Pharmaceuticals' Gross Profit is $1.9 billion, which was up 24.46% from $1.6 billion recorded in FY2023.
  • Alnylam Pharmaceuticals' Gross Profit's 5-year high stood at $1.9 billion during FY2024, with a 5-year trough of $418.7 million in FY2020.
  • Moreover, its 3-year median value for Gross Profit was $1.6 billion (2023), whereas its average is $1.5 billion.
  • Data for Alnylam Pharmaceuticals' Gross Profit shows a peak YoY spiked of 115.05% (in 2020) over the last 5 years.
  • Over the past 5 years, Alnylam Pharmaceuticals' Gross Profit (Yearly) stood at $418.7 million in 2020, then soared by 74.19% to $729.3 million in 2021, then climbed by 23.03% to $897.2 million in 2022, then spiked by 73.87% to $1.6 billion in 2023, then rose by 24.46% to $1.9 billion in 2024.